Interleukin-1 as a therapeutic target in gout

Current Opinion in Rheumatology

Volumn 27, Issue 2, 2015, Pages 156-163

  Dumusc, Alexandre ^a   So, Alexander ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

anakinra; canakinumab; gout; inflammasome; interleukin 1; rilonacept

Indexed keywords

CALCIUM PYROPHOSPHATE; CANAKINUMAB; INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; URIC ACID; ANTIGOUT AGENT; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY;

DRUG COST; DRUG HALF LIFE; GOUT; HOSPITAL PATIENT; HUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ACUTE DISEASE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, GOUTY; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ARTHRITIS, GOUTY; GOUT; GOUT SUPPRESSANTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MOLECULAR TARGETED THERAPY; RECOMBINANT FUSION PROTEINS;

EID: 84922275027     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000143     Document Type: Review

References (39)

1. Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241.
2. Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther 2010; 12:206.
3. Gross O, Yazdi AS, Thomas CJ, et al. Inflammasome activators induce interleukin-1a secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36:388-400.
4. Joosten LAB, Netea MG, Mylona E, et al. Engagement of fatty acids with Tolllike receptor 2 drives interleukin-1b production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010; 62:3237-3248.
5. Mylona EE, Mouktaroudi M, Crisan TO, et al. Enhanced interleukin-1b production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. Arthritis Res Ther 2012; 14:R158.
6. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.
7. Reber LL, Marichal T, Sokolove J, et al. Contribution of mast cell-derived interleukin-1b to uric acid crystal-induced acute arthritis in mice. Arthritis Rheumatol (Hoboken, NJ) 2014; 66:2881-2891.
8. Hua K-F, Chou J-C, Ka S-M, et al. Cyclooxygenase-2 regulates NLRP3 inflammasome-derived IL-1b production. J Cell Physiol 2015; 230:863-874. An interesting study on the negative regulation effect of COX-2 on NLRP3 inflammasome, caspase-1 activity and IL-1b release.
9. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther 2014; 36:1465-1479.
10. Busillo JM, Azzam KM, Cidlowski JA. Glucocorticoids sensitize the innate immune system through regulation of the NLRP3 inflammasome. J Biol Chem 2011; 286:38703-38713.
11. Lee H-M, Kang J, Lee SJ, et al. Microglial activation of the NLRP3 inflammasome by the priming signals derived from macrophages infected with mycobacteria. Glia 2013; 61:441-452.
12. U.S. Food and Drug Administration (FDA). Label approved on 10/23/2013 on kineret [online]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/103950s5150lbl.pdf. [Accessed 23 October 2014]
13. European Medicines Agency (EMA). Rilonacept Regeneron: EPAR - public assessment report. Published
14. November 2009 [online]. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/001047/WC500026509.pdf. [Accessed 23 October 2014]
15. U.S. Food and Drug Administration (FDA). Prescribing information for canakinumab revised on 10/2012 [online]. http://www.accessdata.fda.gov/drug satfda-docs/label/2012/125319s0054.pdf. [Accessed 23 October 2014]
16. Chen K, Fields T, Mancuso CA, et al. Anakinras efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010; 40:210-214.
17. Ghosh P, Cho M, Rawat G, et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken) 2013; 65:1381-1384.
18. Ottaviani S, Molto A, Ea H-K, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 2013; 15:R123.
19. Terkeltaub Ra, Schumacher HR, Carter JD, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013; 15:R25.
20. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomised, single-blind pilot study. Ann Rheum Dis 2009; 68:1613-1617.
21. Schumacher HR, Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012; 64:876-884.
22. Schumacher HR, Evans RR, Saag KG, et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 2012; 64:1462-1470.
23. Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 2013; 52:1285-1292.
24. Sundy JS, Schumacher HR, Kivitz A, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol 2014; 41:1703-1711.
25. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62:3064-3076.
26. Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 2011; 13:R53.
27. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71:1839-1848.
28. Hirsch JD, Gnanasakthy A, Lale R, et al. Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritisrelated health outcomes measures. Int J Clin Pract 2014; 68:1503-1507.
29. Schlesinger N, Mysler E, Lin H-Y, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011; 70:1264-1271.
30. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-1324.
31. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64:1447-1461.
32. French Ministry of Social Affairs and Health [online]. http://medicprix.sante. gouv.fr/medicprix/recherchePresentationInitialisee.do. [Accessed 23 November 2014]
33. Kapur S, Bonk ME. Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. P T 2009; 34:138-141.
34. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008; 58:631-633.
35. Announ N, Palmer G, Guerne P-A, et al. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 2009; 76:424-426.
36. Couderc M, Mathieu S, Glace B, et al. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine 2012; 79:330-331.
37. MoltóA, Ea H-K, Richette P, et al. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Rev Rhum 2012; 79:460-463.
38. Diamantopoulos AP, Brodin C, Hetland H, et al. Interleukin 1 blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J Clin Rheumatol 2012; 18:310-311.
39. Ottaviani S, Brunier L, Sibilia J, et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine 2013; 80:178-182.